Loading clinical trials...
Loading clinical trials...
A Phase 1, Placebo-controlled, Dose-escalation Study of the Safety, Pharmacokinetics, and Antiviral Activity of a Potent Neutralizing Monoclonal Antibody in Individuals With Chronic Hepatitis B Infection
Conditions
Interventions
HepB mAb19
Sterile Saline
Locations
2
United States
NYU Langone Health
New York, New York, United States
The Rockefeller University
New York, New York, United States
Start Date
August 7, 2023
Primary Completion Date
December 1, 2027
Completion Date
March 30, 2028
Last Updated
February 2, 2026
NCT07417553
NCT02932150
NCT07024641
NCT06671093
NCT07275554
NCT03826433
Lead Sponsor
Rockefeller University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions